HLA double match: £1.37M NHS aim to cut 100 kidney rejections

The immunology behind post-transfusion HLA sensitisation is a familiar failure mode in transplant medicine. By translating closer HLA matching into routine transfusion practice for kidney transplant patients, NHSBT is moving a longstanding laboratory insight into frontline clinical care — with early pilots at two London hospitals now expanding nationwide.

The NHS is set to launch a £1.37 million 'double match' programme across England that will match blood donors to kidney transplant patients by both blood type and white blood cell type — also known as tissue type or HLA type — in an effort to reduce transplant rejections. NHS Blood and Transplant (NHSBT) said the service, first piloted at Hammersmith Hospital and the Royal Free in London, could prevent up to 100 kidney transplants being rejected each year. The rollout follows what NHSBT described as a successful pilot scheme and will eventually be supported by partner blood services in Scotland, Wales and Northern Ireland.

“

NHS Blood and Transplant (NHSBT) said the service, first piloted at Hammersmith Hospital and the Royal Free in London, could prevent up to 100 kidney transplants being rejected each year.

Around two in every five kidney transplant patients need blood transfusions before or after their transplant. Transfusion can expose recipients to non-self HLA antigens, and some patients develop antibodies as a result. If those antibodies are directed against the newly donated kidney, the chance of organ rejection rises. Matching white blood cell type as closely as possible between the blood donor and the organ transplant patient is intended to reduce that immunologic risk. Dr Colin Brown, programme lead and consultant clinical scientist at NHSBT, said blood transfusions save lives but carry a particular risk for people on the transplant waiting list.

The intervention targets a deadly bottleneck. Around 250 to 300 people die waiting for a kidney transplant each year, and the waiting list reached an all-time high during 2026. Reducing 100 rejections annually would not directly shorten the queue, but it could preserve scarce organs, improve graft survival and spare patients from the severe consequences of rejection. Each avoided rejection also reduces downstream NHS activity, including re-transplantation, increased dialysis dependence and longer hospital stays.

Operationally, the rollout is a measured scale-up. NHSBT is spending £1.37 million to expand the service across England, with initial implementation focused on all kidney transplant patients at Hammersmith Hospital and the Royal Free before the rest of England. The two London centres serve as demonstration sites, and their experience is likely to shape protocols for wider adoption. Partner blood services in the other UK countries will be expected to provide HLA-matched blood, making this a coordinated national rather than England-only effort.